Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.
J Antimicrob Chemother. 2006 Aug; 58(2):332-7
Susan Swindells
17 May 2012
|
New Finding
This study shows that the tuberculosis drug SQ109 is synergistic with isoniazid, rifampicin, and TMC207 and has activity against ethambutol-resistant strains in vitro. SQ109 has a dual mechanism of action: it blocks cell wall synthesis and prevents the efflux of companion drugs from macrophages.
INDIVIDUAL SUBSCRIPTIONS
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.
Subscribe for $9.95/monthINSTITUTIONAL SUBSCRIPTIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
Recommend to your LibrarianIf you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.
Request an Institutional Trialyour institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.